Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Venture Financing 20
Arrivo BioVentures Raises USD49 Million in Venture Financing 20
Alize Pharma Raises USD1.9 Million in Venture Financing 21
Alize Pharma Raises USD6.4 Million in Series A Financing 22
Celator Pharma Raises US$39 Million In Venture Financing 23
Alize Pharma Raises US$4 Million In Venture Financing 24
Partnerships 25
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 25
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 26
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 28
Merger 29
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 29
Licensing Agreements 31
Jazz Pharma Enters into License Agreement with XL-protein 31
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 32
Jazz Pharma Amends Licensing Agreement with Pfenex 33
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 35
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 36
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 38
Equity Offering 39
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 39
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 41
Debt Offering 43
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 43
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 44
Asset Transactions 45
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 45
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 46
Aytu BioScience Acquires ProstaScint from Jazz Pharma 47
Essex Bidco Acquires Assets from Jazz Pharma 48
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 50
Meda Completes Acquisition Of Womens Health Business From Jazz Pharma For US$95 Million 51
Acquisition 53
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 53
Jazz Pharma Acquires Alize Pharma 55
AstraZeneca May Acquire Ariad Pharma 56
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 58
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 60
Jazz Pharmaceuticals Plc - Key Competitors 63
Jazz Pharmaceuticals Plc - Key Employees 64
Jazz Pharmaceuticals Plc - Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Recent Developments 67
Financial Announcements 67
May 08, 2018: Jazz Pharmaceuticals Reports First Quarter 2018 Financial Results 67
Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results 69
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 71
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 72
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 73
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 75
Corporate Communications 77
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 77
Product News 78
08/03/2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) 78
08/03/2017: Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update 79
03/19/2018: Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos (CPX-351) outside the United States 80
02/08/2018: National Comprehensive Cancer Network adds Jazz Pharmaceuticals Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology 81
Product Approvals 82
Nov 03, 2017: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia 82
May 31, 2017: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status 83
Apr 03, 2017: Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia 84
Clinical Trials 85
Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Vyxeos at ASH 2017 Annual Meeting 85
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89

List Of Tables

List of Tables
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Arrivo BioVentures Raises USD49 Million in Venture Financing 20
Alize Pharma Raises USD1.9 Million in Venture Financing 21
Alize Pharma Raises USD6.4 Million in Series A Financing 22
Celator Pharma Raises US$39 Million In Venture Financing 23
Alize Pharma Raises US$4 Million In Venture Financing 24
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 25
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 26
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 28
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 29
Jazz Pharma Enters into License Agreement with XL-protein 31
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 32
Jazz Pharma Amends Licensing Agreement with Pfenex 33
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 35
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 36
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 38
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 39
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 41
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 43
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 44
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 45
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 46
Aytu BioScience Acquires ProstaScint from Jazz Pharma 47
Essex Bidco Acquires Assets from Jazz Pharma 48
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 50
Meda Completes Acquisition Of Womens Health Business From Jazz Pharma For US$95 Million 51
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 53
Jazz Pharma Acquires Alize Pharma 55
AstraZeneca May Acquire Ariad Pharma 56
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 58
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 60
Jazz Pharmaceuticals Plc, Key Competitors 63
Jazz Pharmaceuticals Plc, Key Employees 64
Jazz Pharmaceuticals Plc, Other Locations 65
Jazz Pharmaceuticals Plc, Subsidiaries 65

List Of Figures

List of Figures
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Jazz Pharmaceuticals: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Jazz Pharmaceuticals Plc (JAZZ) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem,

USD 250 View Report

GW Pharmaceuticals Plc (GWPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The companys commercialized product, Sativex is a plant-derived

USD 250 View Report

GW Pharmaceuticals Plc (GWPH) - Medical Equipment - Deals and Alliances Profile

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The companys commercialized product, Sativex is a plant-derived

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available